Literature DB >> 7609106

Intraoperative blood loss and prognosis in prostate cancer patients undergoing radical retropubic prostatectomy.

M G Oefelein1, L A Colangelo, A W Rademaker, K T McVary.   

Abstract

PURPOSE: To assess more thoroughly the prognostic significance of perioperative transfusions, we examined a previously ignored factor, namely intraoperative blood loss.
MATERIALS AND METHODS: Univariate and multivariate stepwise regression analysis was performed on results of a 10-year series of 251 consecutive men who underwent radical retropubic prostatectomy for clinically localized carcinoma.
RESULTS: Gleason score, operative blood loss and pathological stage were significantly (p < 0.0001) associated with progression-free survival. A risk ratio of 1.08 (95% confidence interval 1.05 to 1.10) was demonstrated for every 100 ml. of operative blood loss.
CONCLUSIONS: The operative blood loss but not the type (autologous or allogeneic) of blood transfused was significantly related to decreased recurrence-free survival after radical retropubic prostatectomy. This finding implies that the operative events necessitating transfusion are potentially more significant than the immunological effects of the transfusion.

Entities:  

Mesh:

Year:  1995        PMID: 7609106     DOI: 10.1097/00005392-199508000-00029

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  14 in total

1.  Impact of intraoperative blood loss on survival after curative resection for gastric cancer.

Authors:  Yue-Xiang Liang; Han-Han Guo; Jing-Yu Deng; Bao-Gui Wang; Xue-Wei Ding; Xiao-Na Wang; Li Zhang; Han Liang
Journal:  World J Gastroenterol       Date:  2013-09-07       Impact factor: 5.742

2.  [New concept minimizes bleeding in radical retropubic prostatectomy].

Authors:  M Schostak; K Matischak; M Schäfer; M Müller; M Schrader; F Christoph; K Miller
Journal:  Urologe A       Date:  2005-11       Impact factor: 0.639

3.  Early recurrence of pseudomyxoma peritonei following treatment failure of cytoreductive surgery and perioperative intraperitoneal chemotherapy is indicative of a poor survival outcome.

Authors:  Terence C Chua; Winston Liauw; David L Morris
Journal:  Int J Colorectal Dis       Date:  2011-08-19       Impact factor: 2.571

4.  Intraoperative blood transfusion contributes to decreased long-term survival of patients with esophageal cancer.

Authors:  Yoshihiro Komatsu; Hajime Orita; Mutsumi Sakurada; Hiroshi Maekawa; Toshitaka Hoppo; Koichi Sato
Journal:  World J Surg       Date:  2012-04       Impact factor: 3.352

5.  Impact of intraoperative blood loss on long-term survival after lung cancer resection.

Authors:  Haruhiko Nakamura; Hisashi Saji; Noriaki Kurimoto; Takuo Shinmyo; Rie Tagaya
Journal:  Ann Thorac Cardiovasc Surg       Date:  2014-02-28       Impact factor: 1.520

Review 6.  Inflammatory response, immunosuppression, and cancer recurrence after perioperative blood transfusions.

Authors:  J P Cata; H Wang; V Gottumukkala; J Reuben; D I Sessler
Journal:  Br J Anaesth       Date:  2013-05       Impact factor: 9.166

Review 7.  The impact of obesity on prostate cancer.

Authors:  Joep G H van Roermund; J Alfred Witjes
Journal:  World J Urol       Date:  2007-05-30       Impact factor: 4.226

8.  Electrothermal bipolar coagulation for radical prostatectomies and cystectomies: a preliminary case-controlled study.

Authors:  George Daskalopoulos; Ioannis Karyotis; Ioannis Heretis; Dimitrios Delakas
Journal:  Int Urol Nephrol       Date:  2004       Impact factor: 2.370

Review 9.  Clinical experiences and current evidence for therapeutic recombinant factor VIIa treatment in nontrauma settings.

Authors:  R Michael Grounds; Charles Bolan
Journal:  Crit Care       Date:  2005-10-07       Impact factor: 9.097

10.  Perioperative Blood Transfusion as a Significant Predictor of Biochemical Recurrence and Survival after Radical Prostatectomy in Patients with Prostate Cancer.

Authors:  Jung Kwon Kim; Hyung Suk Kim; Juhyun Park; Chang Wook Jeong; Ja Hyeon Ku; Hyun Hoe Kim; Cheol Kwak
Journal:  PLoS One       Date:  2016-05-09       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.